Suppr超能文献

[中医药治疗阿尔茨海默病随机对照试验结局指标现状分析]

[Analysis of current situation of outcome indicators in randomized controlled trials on traditional Chinese medicine in treatment of Alzheimer's disease].

作者信息

Wu Qian-Yan, Xu Xiao-Gang, Zhang Qing-Yuan, Huang Sheng-He, Zhang De-Lin

机构信息

College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine Nanchang 330004, China.

College of Clinical Medicine, Jiangxi University of Chinese Medicine Nanchang 330004, China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2024 Jun;49(11):3113-3124. doi: 10.19540/j.cnki.cjcmm.20240218.501.

Abstract

This study aims to analyze the current situation of outcome indicators in randomized controlled trial(RCT) of traditional Chinese medicine(TCM) treatment for Alzheimer's disease(AD), so as to provide a reference for establishing a core indicator set in this field. The researchers systematically searched CNKI, Wanfang, VIP, Sino Med, EMbase, PubMed, Medline, and Cochrane Library. Independent screening of literature and extraction of information was conducted according to the inclusion and exclusion criteria. In addition, the Ro B 2. 0 tool was used for bias risk assessment. A total of 78 RCTs were included, involving 6 379 patients,with 122 kinds of outcome indicators. According to functional attributes, the outcome indicators could be categorized into seven groups:TCM diseases(3 kinds, 13 times), symptoms and signs(26 kinds, 196 times), physical and chemical tests(68 kinds, 149 times),qua-lity of life(1 kind, 2 times), long-term prognosis(2 kinds, 2 times), economic evaluation(0 kind), safety events(21 kinds,194 times), and other indicators(1 kind, 1 time). The results show that the literature evaluation of RCTs of TCM treatment for AD is generally risky, and there are some problems in the selection of outcome indicators, such as lack of TCM characteristics, insignificant distinction between primary and secondary outcome indicators, lack of long-term prognosis and economic evaluation indicators, and non-standard safety event reports. It is suggested that future researchers should establish a core indicator set for AD that highlights the characteristics of TCM and then work to improve the quality of clinical trials.

摘要

本研究旨在分析中医药治疗阿尔茨海默病(AD)随机对照试验(RCT)中结局指标的现状,为该领域核心指标集的建立提供参考。研究人员系统检索了中国知网、万方、维普、中国生物医学文献数据库、Embase、PubMed、Medline和Cochrane图书馆。根据纳入和排除标准独立筛选文献并提取信息。此外,使用Ro B 2. 0工具进行偏倚风险评估。共纳入78项RCT,涉及6379例患者,有122种结局指标。根据功能属性,结局指标可分为七组:中医疾病(3种,13次)、症状体征(26种,196次)、理化检查(68种,149次)、生活质量(1种,2次)、远期预后(2种,2次)、经济评价(0种)、安全事件(21种,194次)及其他指标(1种,1次)。结果表明,中医药治疗AD的RCT文献评价总体风险较高,结局指标选择存在一些问题,如缺乏中医特色、主次结局指标区分不明显、缺乏远期预后和经济评价指标以及安全事件报告不规范等。建议未来研究人员建立突出中医特色的AD核心指标集,进而努力提高临床试验质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验